vobramitamab duocarmazine 2.0 mg (Arm A)

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Castration-Resistant Prostatic Cancer

Drug Information

Target Indication

Castration-Resistant Prostatic Cancer

Clinical Trial

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

MGNX

MacroGenics, Inc.

Related Pipeline

Type 1 Diabetes Mellitus

HER-2 Positive Breast Cancer

Gastric Cancer

Gastric Cancer

Androgen-Independent Prostatic Cancer